Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Answer about the linker

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Mar 09, 2021 1:24pm

78 Views

Post# 32753766

RE:RE:RE:Answer about the linker

Ours is far more beautiful a picture. In all seriousness, this really was an important piece of the puzzle and your explanation is very helpful and a key component to whether this thing works well or not. It's really the essential piece along with how well it homes in on Sortilin since we know the toxin is the toxin. This makes me add a bit more to the probability of success, knowing full well it's still quite low until we start trials. Very, very helpful stuff here.

jfm1330 wrote: Just to make things clearer about the linkers. This is the one used in zoptarelin (glutaryl)

https://spectrabase.com/compound/2hThxt1mJSH

And this is the one used in TH1902 (dimethyl glutaryl)

https://spectrabase.com/compound/6JqpwoZbYZK

These are the diacid forms (not linked). So the two added methyl groups in the middle of the molecule (the V shape up), makes it harder for the catalytic pocket of esterases enzymes to access the carbobyl groups (C=O), hence, the slower catalytic rate. I think these images make it easier to understand for non biochemists.